A 48-hour-old preterm neonate (34 weeks gestation) with ABO incompatibility (mother O, baby B) presents with a serum bilirubin of 16 mg/dL and rising rapidly. Phototherapy is being initiated. Which medication should be administered concurrently to reduce hemolysis and prevent further bilirubin rise?

Explanation

## IVIG in Hemolytic Neonatal Jaundice ### Indications for IVIG **Key Point:** IVIG is the first-line adjunctive therapy in hemolytic disease (Rh or ABO incompatibility) to reduce hemolysis and prevent the need for exchange transfusion. **High-Yield:** IVIG mechanism: - Blocks Fc receptors on fetal RBCs, preventing maternal IgG antibody-mediated hemolysis - Reduces the rate of bilirubin rise by 1–2 mg/dL per day - Decreases the need for exchange transfusion by ~50% when used with phototherapy ### Dosing and Administration - **Dose:** 0.5–1 g/kg IV over 2–4 hours - **Timing:** Administer as soon as hemolytic disease is confirmed, alongside phototherapy - **Efficacy:** Most effective when given early (within first 24–48 hours of life) ### Clinical Scenario Analysis In this preterm infant with ABO incompatibility: - Phototherapy alone may be insufficient due to rapid bilirubin rise - IVIG reduces hemolysis and buys time to prevent exchange transfusion - Preterm infants have lower phototherapy thresholds, making IVIG particularly valuable ### Comparison: IVIG vs. Other Interventions in Hemolytic Disease | Intervention | Mechanism | Onset | Indication | |---|---|---|---| | IVIG | Blocks Fc receptors, reduces hemolysis | 6–12 hours | ABO/Rh incompatibility, rising bilirubin | | Phototherapy | Converts bilirubin to water-soluble isomers | Immediate | All hyperbilirubinemia | | Exchange transfusion | Removes bilirubin + antibodies | Immediate | Severe/refractory hyperbilirubinemia | | Phenobarbital | Induces conjugation | 24–48 hours | Rarely used; delayed onset | **Clinical Pearl:** IVIG is particularly effective in ABO incompatibility (where hemolysis is typically mild-to-moderate) compared to Rh incompatibility. Early administration in preterm infants can prevent escalation to exchange transfusion. ### Why Other Options Are Incorrect - **Phenobarbital:** Slow onset (24–48 hours); not suitable for acute hemolytic disease - **Ursodeoxycholic acid:** No role in hemolytic disease or acute hyperbilirubinemia - **Folic acid:** Not indicated; no effect on hemolysis or bilirubin metabolism